On the molecular origins of the chronic myeloproliferative disorders: It all makes sense

Blood

Volumn 105, Issue 11, 2005, Pages 4187-4190

  Kaushansky, Kenneth ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR A; PROTEIN KINASE; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; DIAGNOSTIC TEST; EOSINOPHILIC LEUKEMIA; HEMATOPOIETIC STEM CELL; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAST CELL LEUKEMIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THROMBOCYTHEMIA;

EID: 19344362958     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1287     Document Type: Review

References (45)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
2. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
3. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 2004;11:58-64.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet. 2005;365:1054-1061.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. Prepublished on March 24, 2005, as DOI 10.1016/..2005.03.023.
6. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. Pre-published on March 27, 2005 as DOI 10.1038/nature03546.
7. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913-916.
8. Prchal JF, Axelrad AA. Letter: bone-marrow responses in polycythemia vera. N Engl J Med. 1974;290:1382.
9. Longmore G. Erythropoietin receptor mutations and Olympic glory. Nat Genet. 1993;4:108-109.
10. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614-621.
11. Cazzola M, Skoda RC Translational pathophysiology: a novel molecular mechanism of human disease. Blood. 2000;95:3280-3288.
12. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198-4200.
13. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA. 2004;101:11444-11447.
14. Zanjani ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest. 1977;59:841-848.
15. Mittelman M, Gardyn J, Carmel M, Malovani H, Barak Y, Nir U. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leuk Res. 1996;20:459-466.
16. Dai CH, Krantz SB, Dessypris EN, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera, II: hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80:891-899.
17. Dai CH, Krantz SB, Koury ST, Kollar K. Polycythaemia vera, IV: specific binding of stem cell factor to normal and polycythaemia vera highly purified erythroid progenitor cells. Br J Haematol. 1994;88:497-505.
18. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994;83:99-112.
19. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310-3321.
20. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57:277-285.
21. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992;70:313-322.
22. Ihle JN. Cytokine receptor signaling. Nature. 1995;377:591-594.
23. Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86:1603-1607.
24. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-993.
25. Berchtold S, Moriggl R, Gouilleux F, et al. Cytokine receptor- independent, constitutively active variants of STAT5. J Biol Chem. 1997;272:30237-30243.
26. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 2001;14:27-37.
27. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell. 2003;14:1448-1459.
28. Luo H, Rose P, Barber D, et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol. 1997;17:1562-1571.
29. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol. 2004;24:4955-4967.
30. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev. 1997;77:759-803.
31. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood. 2005;105:600-608.
32. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferate signals. Cell. 1995;80:729-738.
33. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet. 1993;4:124-129.
34. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem. 2004;279:821-824.
35. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29:694-702.
36. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564-571.
37. Dai C, Chung IJ, Krantz SB. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol. 2005;33:152-158.
38. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985;315:758-761.
39. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the fits gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
40. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
41. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
42. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the C-Mpl ligand, thrombopoietin. Blood. 1995;86:4054-4062.
43. Van Os E, Wu YP, Pouwels JG, et al. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol. 2003:121:482-490.
44. Drachman J, Griffin JD, Kaushansky K. Stimulation of tyrosine kinase activity by MPL-ligand (thrombopoietin). J Biol Chem. 1995;270:4979-4982.
45. Kralovics R, Passamonti F, Buser AS, et al. Again-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.